Surgical Science demonstrated a solid Q1 which prompted a reasonable share price reaction. However, we expect the share to continue trading on undemanding multiples until additional quarterly reports can support the 2027 financial target and regain investor confidence in the business model’s resilience and the company’s moats.
LÄS MER
